Post-earnings recap
Reported
Thu, May 2, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss of $0.07 per share, but the stock rose by 3.95% following the earnings release. The increase in stock price may reflect investor optimism about the company's ongoing clinical projects, despite the lack of revenue data and specific guidance. Overall, the market seems to be responding positively to the management's focus on future developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to progressing their clinical initiatives. They emphasized the importance of their current projects but did not provide specific guidance.
We are focused on advancing our clinical programs.
Our team remains dedicated to delivering value to our stakeholders.